Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Added: 4 months ago Source:  Radcliffe Cardiology
AUTHOR: Greg GuilloryThe selection of drug-eluting stents (DES) for percutaneous coronary intervention (PCI) involves balancing efficacy against safety. The SORT OUT XI randomised trial aimed to compare a newer-generation biolimus-eluting stent with a contemporary dual-therapy sirolimus-eluting stent in a real-world patient population, providing crucial head-to-head evidence.¹SORT OUT XI was a… View more

Intervention

MI/ACS
Stent Underexpansion and Aorto-ostial Lesions Management
Author(s): Luca Paolucci , Asad Shabbir , Marco Lombardi , et al Added: 10 months ago

Imaging & Diagnostics

Intervention
EuroPCR 24: The ABILITY Study
Author(s): Roxana Mehran Added: 1 year ago
EuroPCR 24 - Dr Roxana Mehran (Mount Sinai Hospital, US) outlines the findings of the ABILITY Global Diabetes study onsite at EuroPCR 2024.The ABILITY study (NCT04236609) aimed to evaluate the efficacy and safety of the Abluminus DES+ Sirolimus Eluting Stent System (SES) as compared to the XIENCE Everolimus Eluting Coronary Stent System in diabetic patients eligible for percutaneous coronary… View more

Intervention
TCT 2025: SELUTION DeNovo: 1-Year Results Comparing Sirolimus Balloon vs DES in PCI
Author(s): Christian Spaulding Added: 2 weeks ago
TCT 2025 — Prof Christian M Spaulding (European Hospital Georges Pompidou & INSERM U 970, FR), principal investigator of the SELUTION DeNovo trial (M.A. Med Alliance S.A.; NCT04859985), joins us to share the one year results.This international, multicentre randomised trial enrolled over 3,300 patients at 50 sites across Europe and Asia to compare a sirolimus-eluting balloon (SEB) plus provisional… View more

Intervention
ISET 25: Drug Delivery Devices: Paclitaxel Drug-Coated Balloons and Drug-Eluting Stents
Author(s): Marianne Brodmann Added: 9 months ago
ISET 2025 - How have drug delivery devices changed over the years, and what are the novel technologies and therapeutic agents?Dr Marianne Brodmann (Medical University of Graz, AT) joins us onsite at ISET 2025 to discuss the current landscape of drug delivery devices, from paclitaxel drug-coated balloons to drug-eluting stents. Dr Brodmann discusses evolving technologies, including bioresorbable… View more

Vascular Disease and Surgery

Intervention
Consequences and Management of Excessive Ostial Stent Protrusion
Author(s): Arditya Damarkusuma , Paula Mota , Billal Patel , et al Added: 1 year ago

Imaging & Diagnostics

Intervention
TCT 25: LIFE-BTK: The Esprit™ BTK Drug-Eluting Resorbable Scaffold for Infrapopliteal Lesions
Author(s): Sahil Parikh Added: 2 weeks ago
TCT 2025 - Three-year findings from LIFE-BTK show the Esprit™ BTK scaffold is a durable and effective treatment option for patients with CLTI.Dr Sahil Parikh (Columbia University Vagelos College of Physicians & Surgeons, New York, US) joins us to share the three-year findings from LIFE-BTK (NCT04227899). The randomized controlled trial aimed to evaluate the safety and efficacy of the Esprit™ BTK… View more

Intervention

Vascular Disease and Surgery
TCT 24: Sirolimus- vs. Paclitaxel-Coated Balloon Angioplasty
Author(s): Ulf Teichgräber Added: 1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of the trial shows that percutaneous transluminal angioplasty (PTA) with the sirolimus drug coated balloon (DCB) in patients with femoropopliteal artery disease was/was not noninferior to PTA with the paclitaxel DCB.Prof Ulf Teichgräber joins us onsite at TCT Conference to discuss the findings from the sirolimus- vs. paclitaxel-coated balloon… View more

Intervention

Vascular Disease and Surgery
Consequences and Management of Excessive Ostial Stent Protrusion
Author(s): Arditya Damarkusuma Added: 1 year ago
In this video, Dr Arditya Damarkusuma (Universitas Gadjah Mada, ID) presents his case report on aorto-ostial lesions, recently published in ICR Journal.This case covers the restenosis of a markedly protruding stent at the right coronary ostium in a 54-year old man, and is unusual in its 10-year longevity. Intravascular ultrasound-guided in-stent restenosis intervention using a wire bumper… View more

Imaging & Diagnostics

Intervention
LINC 2025: 12-Month Amputation and Readmission Rates from TRUE-PTX
Author(s): Marianne Brodmann Added: 9 months ago
LINC 2025 - 12-month amputation and readmission rates from the TRUE-PTX study suggests endovascular revascularisation for peripheral artery disease (PAD) with drug-eluting devices lead to better outcomes than with bare device therapies.Dr Marianne Brodmann (Medical University of Graz, AT) joins us to discuss the TRUE-PTX study evaluating a database of patients in the US with PAD who have recieved… View more

Vascular Disease and Surgery

Intervention